Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Bill Steinman
Contributing Editor

Spanish pharma wins DOJ declination

In an SEC filing this week, Spanish pharmaceutical firm Grifols SA said the DOJ issued an ‘official declination to all inquiries related to the possible violation of the Foreign Corrupt Practices Act (FCPA) that were underway since July 2009.’

It said the investigation related to Talecris, acquired by Grifols in 2011.

‘These investigations started prior to the acquisition of Talecris by Grifols,’ the company said, ‘and correspond to actions carried out when Talecris was part of the Bayer Group.’

Grifols said it has been cooperating with the DOJ by reporting all internal findings about potential FCPA violations.

As reported this week by the Wall Street Journal, an internal investigation at Talecris examined sales in Belarus, Russia, Iran, Brazil, Bulgaria, China, Georgia, Libya, Poland, Turkey, and Ukraine. Talecris had notified the DOJ in 2009 of the investigation and ‘suspended operations in several countries while adding safeguards against foreign bribery, in some cases terminating consultants and distributors,’ the Wall Street Journal said.

Grifols said in issuing the declination, the DOJ mentioned ‘the significant cooperation of Grifols . . . to secure valuable information and making responsible decisions that [led] to the early disclosure of information to the DOJ.’

The company also said it took remedial action and strengthened its compliance program.

Grifols SA’s full FCPA disclosure in its Form 6-K (Report of Foreign Issuer) is here.

Share this post

LinkedIn
Facebook
Twitter

Comments are closed for this article!